Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade

dc.contributor.author	López Soto, Alejandro
dc.contributor.author	González Rodríguez, Segundo
dc.contributor.author	Galluzzi, Lorenzo
dc.date.accessioned	2018-02-28T10:41:35Z
dc.date.available	2018-02-28T10:41:35Z
dc.date.issued	2017
dc.identifier.citation	Oncoimmunology, 6(10), (2017); doi:10.1080/2162402X.2017.1346766
dc.identifier.issn	2162-402X
dc.identifier.uri	http://hdl.handle.net/10651/46347
dc.description.sponsorship	ALS and SG are supported by Spanish Instituto de Salud Carlos III (FIS PI16/01485). LG is supported by an intramural startup from the Department of Radiation Oncology of Weill Cornell Medical College (New York, US), and by Sotio a.c. (Prague, Czech Republic).
dc.language.iso	eng
dc.relation.ispartof	Oncoimmunology, 6
dc.rights	©,
dc.source	WOS:000414520200016
dc.title	Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade
dc.type	journal article
dc.identifier.doi	10.1080/2162402X.2017.1346766
dc.relation.projectID	ISCIII/ FIS PI16/01485
dc.relation.publisherversion	http://dx.doi.org/10.1080/2162402X.2017.1346766

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.